Patents by Inventor Maxine Bauzon
Maxine Bauzon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295596Abstract: Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.Type: ApplicationFiled: November 8, 2022Publication date: September 21, 2023Applicant: COAGULANT THERAPEUTICS CORPORATIONInventors: Maxine BAUZON, Terry HERMISTON
-
Patent number: 11530401Abstract: Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.Type: GrantFiled: June 9, 2020Date of Patent: December 20, 2022Assignee: Coagulant Therapeutics CorporationInventors: Maxine Bauzon, Terry Hermiston
-
Publication number: 20220251237Abstract: The present disclosure provides antibodies specific for glypican-3 (GPC3). Nucleic acids that encode one or both of the variable chain polypeptides of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are useful in various diagnostic, and monitoring applications, which are also provided.Type: ApplicationFiled: July 31, 2020Publication date: August 11, 2022Inventors: David Rabuka, Penelope M. Drake, Yun Cheol Kim, Robyn M. Barfield, Maxine Bauzon
-
Publication number: 20220033514Abstract: The present disclosure provides antibodies specific for Mucin 1. Nucleic acids that encode one or both of the variable chains of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are also useful in various diagnostic, and monitoring applications, which are also provided.Type: ApplicationFiled: July 30, 2021Publication date: February 3, 2022Inventors: David Rabuka, Penelope M. Drake, Yun Cheol Kim, Robyn M. Barfield, Maxine Bauzon, Ayodele Ogunkoya
-
Publication number: 20210113657Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.Type: ApplicationFiled: December 18, 2020Publication date: April 22, 2021Applicant: GLADIATOR BIOSCIENCES, INC.Inventors: Maxine BAUZON, Terry HERMISTON
-
Publication number: 20210062143Abstract: The present disclosure relates to a method of targeting extracellular vesicles employing a molecule comprising a GLA domain and extracellular vesicles obtained or obtainable from a method disclosed herein.Type: ApplicationFiled: September 5, 2018Publication date: March 4, 2021Applicant: GLADIATOR BIOSCIENCES, INC.Inventors: Terry HERMISTON, Maxine BAUZON, Christopher H. CONTAG, Jonathan HARDY, Masamitsu KANADA
-
Patent number: 10925926Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.Type: GrantFiled: October 25, 2018Date of Patent: February 23, 2021Assignee: GLADIATOR BIOSCIENCES, INC.Inventors: Maxine Bauzon, Terry Hermiston
-
Publication number: 20210015900Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.Type: ApplicationFiled: September 25, 2020Publication date: January 21, 2021Applicant: GLADIATOR BIOSCIENCES, INC.Inventors: Maxine BAUZON, Terry HERMISTON
-
Patent number: 10894075Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.Type: GrantFiled: March 13, 2014Date of Patent: January 19, 2021Assignee: GLADIATOR BIOSCIENCES, INC.Inventors: Maxine Bauzon, Terry Hermiston
-
Publication number: 20210002624Abstract: Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.Type: ApplicationFiled: June 9, 2020Publication date: January 7, 2021Applicant: Coagulant Therapeutics CorporationInventors: Maxine Bauzon, Terry Hermiston
-
Publication number: 20200407421Abstract: The present disclosure relates to a method of targeting stems cells, in particular non-apoptotic stem cells, employing a GLA domain, capable of binding surface exposed phosphatidyl serine.Type: ApplicationFiled: September 5, 2018Publication date: December 31, 2020Applicant: GLADIATOR BIOSCIENCES, INC.Inventors: Terry HERMISTON, Maxine BAUZON, Christopher H. CONTAG, Jonathan HARDY, Francis Gerard BLANKENBERG
-
Publication number: 20200407422Abstract: The present disclosure relates to a method of intracellular delivery of a molecule employing a GLA domain to facilitate entry into the cell.Type: ApplicationFiled: September 5, 2018Publication date: December 31, 2020Applicant: GLADIATOR BIOSCIENCES, INC.Inventors: Terry HERMISTON, Maxine BAUZON, Christopher H. CONTAG, Jonathan HARDY, Francis Gerard BLANKENBERG
-
Patent number: 10717970Abstract: Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.Type: GrantFiled: September 14, 2016Date of Patent: July 21, 2020Assignee: Coagulant Therapeutics CorporationInventors: Maxine Bauzon, Terry Hermiston
-
Patent number: 10273466Abstract: Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.Type: GrantFiled: July 25, 2014Date of Patent: April 30, 2019Assignee: BAYER HEALTHCARE LLCInventors: Maxine Bauzon, Terry Hermiston
-
Publication number: 20190105370Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.Type: ApplicationFiled: October 25, 2018Publication date: April 11, 2019Applicant: GLADIATOR BIOSCIENCES, INC.Inventors: Maxine BAUZON, Terry HERMISTON
-
Publication number: 20170296624Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.Type: ApplicationFiled: June 23, 2017Publication date: October 19, 2017Applicant: Bayer HealthCare LLCInventors: Maxine BAUZON, Terry HERMISTON
-
Patent number: 9694048Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.Type: GrantFiled: March 13, 2014Date of Patent: July 4, 2017Assignee: BAYER HEALTHCARE, LLCInventors: Maxine Bauzon, Terry Hermiston
-
Publication number: 20160376578Abstract: Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.Type: ApplicationFiled: September 14, 2016Publication date: December 29, 2016Applicant: BAYER HEALTHCARE LLCInventors: Maxine BAUZON, Terry Hermiston
-
Publication number: 20160106806Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.Type: ApplicationFiled: March 13, 2014Publication date: April 21, 2016Inventors: Maxine BAUZON, Terry HERMISTON
-
Publication number: 20160008482Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.Type: ApplicationFiled: March 13, 2014Publication date: January 14, 2016Inventors: Maxine BAUZON, Terry HERMISTON